|
|
Links
>
Avastin (Anti-VEGF)
| Name |
Creator |
Bevacizumab (Avastin™) Improves Survival in Metastatic Colorectal Cancer
Patients with newly diagnosed metastatic colon cancer who received the therapeutic agent bevacizumab (Avastin™) along with the chemotherapy combination known as IFL had substantially longer overall survival times than patients who received IFL but with a placebo instead of bevacizumab. With these results, bevacizumab becomes the first anti-angiogenesis agent to prove effective in a randomized Phase III trial.
http://www.cancer.gov/clinicaltrials/results/bevacizumab-and-colorectal-cancer0601 |
altman23
|
Cancer-Starving Drug Shows Promise
In the new study Avastin was added to traditional chemotherapy in about 400 patients with previously untreated advanced colon cancer. In another 400 patients, the colon cancer treatment consisted of standard chemotherapy without Avastin, says Hurwitz.
http://my.webmd.com/content/article/66/79563.htm |
altman23
|
Drug Duels Avastin Vs. Erbitux
Both drugs made big comebacks last spring. A European trial confirmed that Erbitux shrank tumors in 22.9% of advanced colon cancer patients, at least when combined with chemotherapy. Separately, Genentech revealed that Avastin in combination with chemotherapy extended colon cancer patients' lives by five months in a trial of 900 patients. Both companies have rushed in applications to the FDA for marketing approval, which seems almost certain. At least initially, the two drugs will not be direct competitors. Avastin will be for "first-line" use in patients after they are initially diagnosed with advanced colon cancer, while Erbitux will be used in patients who have already failed other drug regimens.
http://forbesbest.com/technology/sciences/2003/12/04/cz_rl_1204avastin.html |
altman23
|
New Cancer Drugs Open Up New Era in Treatment
Avastin enabled patients with advanced colorectal cancer to live nearly 5 months longer. 412 patients who received Avastin in a study lived an approximate average of 20 months, compared with 16 months for 403 similar patients receiving traditional chemotherapy alone.
http://www.canhope.com.sg/news_events/new_cancer.html |
altman23
|
Phase II, randomized trial comparing bevacizumab plus FU/LV with FU/LV alone in patients with metastatic colorectal cancer
J Clin Oncol. 2003 Jan 1;21(1):60-5 Compared with the FU/LV control arm, treatment with bevacizumab (at both dose levels) plus FU/LV resulted in higher response rates (control arm, 17%, 95% confidence interval [CI], 7% to 34%; low-dose arm, 40%, 95% CI, 24% to 58%; high-dose arm, 24%, 95% CI, 12% to 43%), longer median time to disease progression (control arm, 5.2 months, 95% CI, 3.5 to 5.6 months; low-dose arm, 9.0 months, 95% CI, 5.8 to 10.9 months; high-dose arm, 7.2 months, 95% CI, 3.8 to 9.2 months), and longer median survival (control arm, 13.8 months; 95% CI, 9.1 to 23.0 months; low-dose arm, 21.5 months, 95% CI, 17.3 to undetermined; high-dose arm, 16.1 months; 95% CI, 11.0 to 20.7 months).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12506171&dopt=Abstract |
altman23
|
|
